Latest AbbVie Stories

Analysis Evaluates Response Rates in Patients with 17p Deletion, Fludarabine-Refractory CLL NORTH CHICAGO, Ill., June 17, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). High-risk CLL patients...

Multinational, Multidisciplinary Expert Panel Reveals Survey Findings, Asks Patients to Take Pledge as Part of RA: Join the Fight, an AbbVie Global Initiative MADRID, June 11, 2013 /PRNewswire/ -- RA: Join the Fight today presented at a launch event in Madrid the findings from the largest global rheumatoid arthritis (RA) patient survey, which included 10,171 patients across 42 countries. Findings show that while a majority of RA patients (74 percent) say they know a great deal or a...

NORTH CHICAGO, Ill., June 5, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 34(th) Annual Goldman Sachs Global Healthcare Conference on Thursday, June 13, 2013. Bill Chase, executive vice president and chief financial officer, and Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 12:40 p.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor...

Data in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma NORTH CHICAGO, Ill., June 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States, and relapsed/refractory non-Hodgkin's lymphoma (NHL)....

Highest Lipase Dose Now Available On the Market NORTH CHICAGO, Ill., May 30, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that a new, higher-dose capsule of CREON(®) (pancrelipase) Delayed-Release Capsules is commercially available in the United States. The U.S. Food and Drug Administration (FDA) recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, swelling of the pancreas that lasts...

NORTH CHICAGO, Ill., May 28, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 2013 Jeffries Global Healthcare Conference on Tuesday, June 4, 2013. Bill Chase, executive vice president and chief financial officer, and Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 8:00 a.m. Central time. A live audio webcast of the question and answer session will be accessible through AbbVie's Investor Relations Web...

AbbVie presents results of Phase 2b studies NORTH CHICAGO, Ill., May 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease (CKD) and type 2 diabetes. SONAR is a large, multinational,...

First selective JAK1 inhibitor to enter Phase 2 studies in Crohn's disease NORTH CHICAGO, Ill. and MECHELEN, Belgium, May 17, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the...

Enrollment in Phase 1 Clinical Trials of ABT-199 in Chronic Lymphocytic Leukemia Continues NORTH CHICAGO, Ill., May 15, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, Chicago. Data being presented include the results from two clinical trials evaluating the safety and...

NORTH CHICAGO, Ill., May 7, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2013 Health Care Conference on Tuesday, May 14, 2013. Bill Chase, executive vice president and chief financial officer, and John M. Leonard, M.D., senior vice president and chief scientific officer, will take part in a question and answer session at 12:40 p.m. Central time. A live audio webcast of the question and answer session will be accessible through...